Antithrombotic After TAVR: No Treatment, No Problem?
- PMID: 36599592
- DOI: 10.1016/j.jcin.2022.11.003
Antithrombotic After TAVR: No Treatment, No Problem?
Keywords: antiplatelet therapy; antithrombotic therapy; bleeding; mortality; stroke; transcatheter aortic valve replacement.
Conflict of interest statement
Funding Support and Author Disclosures Dr Auffret has received lecture fees from Edwards Lifesciences, Medtronic, and Bouchara-Recordati; and has received consulting fees from Boston Scientific. Dr Guedeney has received lecture fees from Bayer; and has received travel expenses from Sanofi. Dr Leurent has been a proctor for and received lecture and consultant fees from Abbott. Dr Didier has received lecture fees from Edwards Lifesciences and General Electric.
Comment on
-
No Antithrombotic Therapy After Transcatheter Aortic Valve Replacement: Insight From the OCEAN-TAVI Registry.JACC Cardiovasc Interv. 2023 Jan 9;16(1):79-91. doi: 10.1016/j.jcin.2022.10.010. Epub 2022 Dec 14. JACC Cardiovasc Interv. 2023. PMID: 36599591
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
